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Background: To compare the analgesic effect of anesthetic infiltration of lidocaine 2% and low-level laser therapy 
(LLLT) by GaAlAs into tender points of patients with orofacial pain and fibromyalgia (FM). 
Material and Methods: A randomized clinical trial was performed with adults (N=66) that were allocated into two 
groups (1:1): Group A received LLLT irradiation by Diode Laser GaAlAs (780nm) with expositions twice a week 
during six weeks and Group B was treated with anesthetic infiltration of lidocaine 2% without vasoconstrictor 
once a week for four weeks. The pain assessment included the Visual Analogic Scale (VAS) and tenderness to 
palpation. 
Results: No dropout and adverse effect was observed during the study. The pain decreased significantly in each 
group after the treatment (p=0.0001, β=1.0), even though no statistical difference was found between both treat-
ments (p=0.46, β= 0.82). The presence of tender points decreased after both treatments, with responsively in some 
types of masticatory muscles (p<0.05) except posterior temporalis muscle. The patients’ perception showed that 
both treatments were effective and a few patients reported that the treatment did not improve welfare. 
Conclusions: The LLLT by GaAlAs and anesthetic infiltration of lidocaine 2% were equally effective to control 
orofacial pain in FM individuals.
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Introduction
Fibromyalgia (FM) is a chronic musculoskeletal condi-
tion characterized by generalized pain with sensitivity 
to palpation in 11 or more of the 18 points at specific 
body locations (tender points) during at least 3 months 
(American College of Rheumatology - ACR) (1). Most 
patients experience fatigue accompanied by depression, 
anxiety, cognitive, sleep and mood disorders (2,3). De-
spite the fact that 0.5% to 5% of the entire population is 
diagnosed with the FM (4) and the significant relevance 
of this condition in the quality of life (5), the therapeutic 
approach remains in many cases insufficiently effec-
tive.
Although the etiology and pathophysiology of fibromy-
algia are unclear, some hypotheses have been postulated. 
Some authors have described the etiology as a dysfunc-
tion of central nervous system, a reduction of activity of 
hypothalamic-pituitary-adrenal axis or a dysfunction of 
skeletal muscle nociception (6). Moreover, the incom-
plete understanding of the etiopathogenetic process of 
FM makes difficult to clinicians the decision-making, 
which should be associated with the treatment need of 
this disorder, the patient’s expectations, the health-relat-
ed quality of life and the symptoms of patients.
As the cure for fibromyalgia is unknown, therapeutics 
should aim to reduce pain and provide a holistic ap-
proach for the patient and their family. In this context, 
a variety of treatment options to relieve fibromyalgia 
symptoms was proposed, such as instruction for the 
patient, psychotherapy, exercises, alternative medicine, 
pharmacologic therapy and LLLT (7,8). However, the 
unclear consensus on the optimal management choice 
and the low evidence of therapeutical protocols might 
be considered a challenge for the clinicians. 
Recent studies suggest that the LLLT have efficient re-
sults of pain relief in patients with fibromyalgia (9,10-14). 
Among these research, only the study of Molina-Torres 
et al. (14) evaluated the effect of LLLT on the treatment 
of orofacial pain in individuals with FM, however, the 
effect size was moderate. Thus, there is no sufficient 
evidence that this type of treatment for orofacial pain 
in FM patients. On the other hand, the anesthesia in-
jection might reduce pain originated from a concomi-
tant tender point in selected patients with fibromyalgia 
who also experience myofascial pain (15). In fact, the 
anesthetic infiltration is the most commonly used treat-
ment for myofascial pain syndrome characterized by 
the presence of trigger points (16). Even though there 
is no randomized clinical trial with sufficient evidence 
to support the use of this therapy in the management of 
tender points in the orofacial region of FM patients.
In this context, this study was conducted to investigate 
the analgesic effects of anesthetic infiltration of lido-
caine 2% and LLLT by GaAlAs into tender points in 
patients with both orofacial pain and FM, associating 
these approaches with the patients’ perception of effec-
tivity of treatment and well-being.
Material and Methods
The present study was registered at the Brazilian clini-
cal trial registrations (RBR-8k5yzn) and follows the 
CONSORT (Consolidated Standards of Reporting Tri-
als) statement for randomized clinical trials (17).
- Ethical Considerations
This study was approved by Ethics Committee in 
Research of Federal University of Paraiba (CAAE: 
08523712.6.0000.5183) and followed all the recommen-
dations of Helsinki Declaration. The clinical approach-
es that might cause any possible discomfort or risk were 
fully explained to the individuals. All the individuals 
who accepted to participate in this study signed a free 
and informed consent. 
- Sample 
The sample size calculation was carried out to pro-
vide a statistically significant difference between the 
experimental groups, using the two-tailed unpaired t-
test. The standard deviations were based on the study 
of Demirkol et al. (18) and were considered the same 
for the two groups (σ1 = σ2= σ). The mean difference 
between the two populations was taken as µ1– µ2, esti-
mating that the clinical relevance of 2 points of the Vi-
sual Analogue Pain Scale (VAS). The power was given 
as 0.9 and the level of significance was 0.05. The sample 
estimative was 56 individuals (n = n1 + n2), equally 
divided into two groups (n1 = n2), considering the ap-
plication of the following formula as Röhrig et al., (19) 
suggest: (Fig. 1).
𝑛𝑛1 = 𝑛𝑛2 =
2(𝑍𝑍!"#$% − 𝑍𝑍!!∝)
2 (µ1–  µ2)
σ
! 	
The initial sample size calculation was increased by 
20% to compensate possible losses during the treatment 
application, resulting in 66 volunteers necessary to per-
form such evaluation. Individuals with FM diagnosis 
and pain in the orofacial region were initially selected 
from a database of two centers of orofacial pain (one 
public and one private), located in a small capital of the 
Northeast of Brazil. 
The sample was allocated into 2 groups (1:1): Group A 
(n=33) received LLLT and Group B (n=33) was treated 
by anesthetic infiltration. The block randomization was 
performed in Microsoft® Excel® 2016 software after 
the codification of each volunteer. This phase was ac-
complished by a research blinded and every member of 
the population had an equal chance of being chosen.
Fig. 1: Formula.
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- Eligibility Criteria 
To be eligible for this study the patients had to fulfill the 
fibromyalgia diagnosis criteria from the American Col-
lege of Rheumatology 1 and the myalgia diagnostic cri-
teria for temporomandibular disorders (DC/TMD) (20). 
The diagnostic of fibromyalgia and orofacial pain were 
accomplished by a neurologist expert in chronic pain 
and a dentist, respectively. Additionally, the volunteers 
should have sufficient cognitive levels to understand 
procedures, follow instructions without the assistance 
of another person. 
The exclusion criteria considered patients who changed 
their systemic medications 3 months before the begin-
ning of the treatments, those who related the previous 
experience of an allergic reaction to lidocaine or do not 
agree to participate voluntarily in this research. During 
the treatments, if any alteration of the systemic medica-
tion were indicated by the responsible rheumatologist, 
the subject would be excluded from this research. 
- Study Design and Interventions 
A parallel, controlled and randomized clinical trial de-
sign was performed with 66 adults of both genders (62 
women and 4 men). The first author performed both 
types of treatment. Two evaluations, one qualitative 
e another quantitative, were carried out to test treat-
ments’ effectiveness. The quantitative information was 
the measurement of orofacial pain intensity using the 
VAS. The VAS was self-completed by the respondent 
that placed a line perpendicular to the VAS at the point 
that represented their pain intensity. The pain scores 
reported by the patients ranged from 0 (no pain) to 10 
(intense pain). These analyses were conducted on two 
occasions: at the beginning (1 day before the start) and 
at the end of the treatments (1 day after the ending). The 
measure of VAS considered the pain at rest or during 
the function in the last 15 days.
The qualitative information was the tenderness in the 
facial muscles as the primary clinical and diagnostic of 
local pain. Tender points were evaluated by an experi-
ent dentist (expert in Oral and Maxillofacial Surgery) 
that used manual palpation with the perpendicular pres-
sure of two or three fingers on the surface of the skin, 
at approximately 4.0 kg/cm2 as suggested by Wolfe et 
al. (1).  This evaluation was performed with the patient 
in supine position, following the assessment of bilater-
ally points: C posterior masseter muscle, [2] anterior 
masseter muscle, [3] anterior temporal muscle, [4] me-
dium temporal muscle, [5] posterior temporal muscle. 
The presence and location of tender points were marked 
in a diagram that provided a specific condition of the 
patient status before the treatment. This information 
was used as a reference of the applications during all 
the treatment and was repeated at the end of the study.
Before the treatments, the skin of the individuals was 
disinfected with 70% alcohol and marked with a perma-
nent marker at the points assessed in baseline evalua-
tion. Treatment in Group A consisted of irradiation with 
Diode Laser GaAlAs (Twin Flex® MMOptics) based 
on a wavelength of 780nm, 50mW of power, Energy 
2J (Dose 50J / cm2), spot 0,04cm2. The LLLT was ap-
plied precisely and continuously into the selected points 
during approximately 40 seconds. The patients were 
exposed to the laser application in a spot-skin distance 
of 1 cm while seated in a dental chair with their necks 
supported, two weekly sessions, during six weeks, for 
a total of twelve sessions. In the Group B, the individu-
als were treated by anesthetic infiltration of lidocaine 
2% without vasoconstrictor (Lidostesim® SV). Carpule 
syringes with reflux and 30-G short needles (Unoject 
®, DFL) were used in the procedure. A volume of 0.5 
ml of lidocaine was infiltrated into each tender point 
and stretching was made after all the injections in order 
to help to distribute the solution across the muscle. The 
treatment in Group B was repeated once a week for four 
weeks.
The volunteers fulfilled a questionary after treatment 
conclusion to assess information regarding the percep-
tion of the effectiveness of both treatments and well-be-
ing. The questionnaire was structured with categorized 
questions (Yes or No) and following this sequence [1] 
In your opinion, do you think this treatment effective? 
[2] Do you think that this treatment improves your well-
being? The questions were answered individually at the 
clinical office without any patient identification to con-
trol any possible bias.  
- Statistical Analysis 
The primary outcome were the level of pain (VAS) and 
the incidence of pain before and after the treatment. The 
secondary outcome considered the individuals’ percep-
tion. The statistical analysis was carried out in SPSS 
software version 23.0 (SPSS, Inc., Chicago, IL, USA). 
Data were analyzed using descriptive and inferential 
statistics. Normality was obtained by the Shapiro-Wilk 
test. A comparative exploration of the treatments con-
sidering VAS was performed by Student t-test. The 
paired t-test was used to compare each treatment within 
the same group (before and after). The posthoc analysis 
accessed the β-1 value (effect size) using the software 
G*Power 3.1. McNemar’s test was used to access the 
difference between the presence of tenderness before 
and after the treatments. The level of significance ad-
opted was 0.05 considering a two-tailed test. 
Results 
All the volunteers completed the study. There were no 
adverse effects reported under the conditions of this 
study. The average age was 46.14 (± 10.91) years, with 
76% of these individuals diagnosed with FM in the last 
5 years. There was no significant difference between 
the age and gender of participants in both groups, with 
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p-value > 0.05. Table 1 shows a significant decrease of 
pain level in each group after the treatment (p=0.0001, 
β=1.0), even though, no statistical difference was found 
between both treatments (p=0.46, β= 0.82). 
Table 2 and 3 demonstrates that there was a lower fre-
quency of tender points after both treatments, with re-
sponsively in all types of muscles analyzed (p<0.05), ex-
cept for the posterior temporal muscle that did not show 
significant difference after the applications (p>0.05). 
The patient’s perception showed that both treatments 
were effective, with 100% of positive response in Group 
A against 97% in Group B. Regarding the well-being 
after the treatment, 3% (n=1) of the patients in Group A 
related that the treatment did not improve welfare. This 
fact was also observed in Group B with higher propor-
tion 18% (n=6) (Table 4).  None of the volunteers com-






(95% CI) p-value β-value
Group A 7.85 (± 2.22) 2.85 (±1.77) 5.00 (4.13-5.83) 0.0001* 1.00
Group B 8.08 (± 2.03) 3.18 (± 1.87) 4.87 (4.13-5.61) 0.0001* 1.00
Table 1: Average VAS for two study groups before and after treatment.
Right Left
Before After Before After
Yes Yes Yes Yes
n % n % P n % n % p
Posterior Masseter Muscle 21 64 8 26 0.00* 17 52 8 26 0.01*
Anterior Masseter Muscle 14 42 6 19 0.00* 12 36 6 19 0.07
Anterior temporal Muscle 22 67 11 36 0.01* 24 73 11 36 0.00*
Medium Temporal Muscle 22 67 11 36 0.00* 25 76 13 42 0.00*
Posterior Temporal Muscle 28 85 25 81 0.45 28 85 24 78 0.28
Table 2: Frequency distribution of pain before and after treatment with LLLT (Group A) – Multiple responses.
Right Left
Before After Before After
Yes Yes Yes Yes
n % n % p n % n % p
Posterior Masseter Muscle 19 58 5 15 0.00* 15 46 4 12 0.00*
Anterior Masseter Muscle 16 49 2 6 0.00* 13 39 3 9 0.01*
Anterior Temporal Muscle 25 76 14 42 0.00* 25 76 14 42 0.00*
Medium Temporal Muscle 23 70 13 39 0.01* 21 64 13 39 0.06
Posterior Temporal Muscle 29 88 24 73 0.26 30 91 25 76 0.12
Table 3: Frequency distribution of pain before and after treatment with Anesthetic Infiltration (Group B) – Multiple responses.
* Significant difference accessed by Paired t-test.
n-value and % represent the Yes frequency of pain; * Significance of  McNemar’s test.
n-value and % represent the Yes frequency of pain; * Significance of  McNemar’s test. 
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Discussion 
This randomized clinical trial was designed to specifically 
compare the treatment outcome of a pharmacological and 
a non-pharmacological approach. Two important parame-
ters of orofacial pain were assessed as the intensity of pain 
by VAS and the presence and localization of tender points 
by palpation, both recommended by American Dental As-
sociation (ADA). Tender points are considered the primary 
clinical and diagnosis parameter of symptomatology of 
FM, which provides a reliable indicator of orofacial pain 
(21,22). In addition, VAS is a unidimensional, simple e fre-
quently used method for the determination of pain inten-
sity. The test-retest reliability of VAS has been shown to be 
good, as well the sensitivity to detect changes in pain after 
weeks with analgesic therapy (23).
Comparatively, in both groups, a significant decrease of 
pain level was observed (p<0.05), with 64% in Group 
A and 61% in Group B, without statistical difference 
between both treatments (p=0.46, β= 0.82). The LLLT 
(12-14) and anesthetic infiltration (24-26) has been stud-
ied in some modalities of therapies to pain remission in 
individuals with FM, although the comparison by con-
trolled clinical trials and the superiority of each therapy 
are scarce, as well the relation of FM and orofacial pain. 
The only study that evaluated the LLLT in individuals 
with FM and orofacial pain 14 obtained a reduction of 
44% of pain after the treatment using a protocol of 1 
session per week during 12 weeks. Our study obtained 
better results with 2 sessions per week during 6 weeks.
While the mechanisms have not been completely ex-
plained, our study shows that LLLT and anesthetic 
infiltration clearly have an analgesic effect. In trigger 
points, the anesthetic infiltration modulates the pain by 
a reversible blocker of nerve conduction, a mechanical 
disruption of muscle fibers, an interruption of the posi-
tive feedback of chronic pain, a dilution and a clearance 
of nociceptive molecules by vasodilatory effect and vol-
ume administrated (27). On the other hand, the mus-
cular photostimulation by LLLT modulates pain by pe-
ripheral nerve stimulation, microcirculation regulation, 
and release of anti-inflammatory agents (6,8). 
Interestingly, these results demonstrate the relevance 
of orofacial pain in individuals with FM. Pain in the 
craniofacial area has not usually been considered in the 
diagnosis of FM, although, some investigations associ-
ate the facial pain with generalized muscle pain (28,29). 
In this study, there was a regular presence of tenderness 
in soft tissues, principally in temporal and masseter 
muscles. The study of da Silva (30) also observed a 
high prevalence of tender points in masseter and tem-
poral muscle in fibromyalgia patients. The presence of 
FM and myofascial pain in this study emphasizes the 
importance of an individual assessment to identify and 
qualify comorbidities associated with FM, which will 
help the clinicians in disease control.
The considerable reduction of tender points in both groups 
was observed, although there are some of them that were 
not statistically responsive to the treatments. The anes-
thetic infiltration of lidocaine 2% and LLLT by GaAlAs 
showed to be ineffective to decrease the tenderness in 
posterior temporal muscle. This muscle is described as 
the most associated with facial pain in FM patients, with 
high patients’ complaint (26), what might be associated 
with the continuous activity function of temporalis mus-
cle during the mandibular rest and elevation (31). Thus, 
the study of these treatments associated with the physi-
ological function might be interesting to understand the 
muscle responsiveness in patients with FM.
The injections of lidocaine in patients with FM demon-
strates a significant reduction of the facial pain inten-
sity (24,26,32). However, the exact effect of anesthetic 
infiltration is difficult to estimate since the saline so-
lution and dry needling is also considered a treatment 
(32). The LLLT is a physical modality of treatment that 
acts without the necessity of injection and administra-
tion of any pharmacological product. This fact is more 
important when the individual’s perception was consid-
ered (33) as it was observed in our study, which dem-
onstrates that the patient’s perception is more favorable 
to the LLLT with 97% of improvement of well-being 
against 82% to anesthetic infiltration. However, the 
subjective implications of patients’ perception provide 
a bias of satisfaction, principally when considered the 
chronic pain suffering. In this context, the present study 
showed a tendency to the usage of LLLT being more 
accepted, non-invasive and promoting less discomfort 
and adverse effects.
This study has some limitations that emerged from dif-
ficulties naturally observed in clinical trials. Firstly, 
the absence of an extensive follow-up to investigate the 
durability of the analgesic effects of the applications. 
Secondly, the subjectivity of the parameters of clinical 
assessments represents the patients’ personal responses, 
which makes it difficult to standardize, considering that 
pain threshold is variable and unspecific. Thirdly, a con-
trol group was not included because the ethical impos-
sibility of allocating individuals with high levels of pain 
in placebo group. Although it is important emphasizing 
that the control of the eligibility criteria and the follow-
Table 4: Patient’s perception of effectiveness and well-being pro-
vided by the treatments. 









Group A 33 (100) 0 32 (97) 1 (3)
Group B 32 (97) 1 (3) 27 (82) 6 (18)
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up promotes a more homogeneous sample that attenu-
ates the influence of external factors (factors other than 
the treatment).
Conclusions
It can be concluded that this particular type of LLLT 
using GaAlAs (780 nm, 50j/cm2, 50mW of power) with 
the protocol of applications twice a week during 6 weeks 
and the anesthetic infiltration of lidocaine 2% with once 
a week usage during four weeks were equally effective 
approaches to pain reduction in individuals with orofa-
cial pain and FM. However, the usage of LLLT might be 
more interesting considering the patient’s comfort.
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